backgroundpolyomaviru
nephropathi
pvan
common
caus
kidney
allograft
dysfunct
loss
identifi
pvanspecif
gene
express
underli
molecular
mechan
analyz
kidney
biopsi
without
pvan
studi
includ
posttranspl
renal
allograft
biopsi
cell
mediat
normal
function
graft
sta
interstiti
fibrosistubular
atrophi
ifta
uniqu
kidney
allograft
recipi
perform
gene
express
assay
bioinformat
analysi
identifi
set
pvanspecif
gene
valid
relev
subset
gene
valid
qpcr
ihc
resultsunsupervis
hierarch
cluster
analysi
biopsi
reveal
high
similar
pvan
tcmr
gene
express
increas
statist
stringenc
identifi
uniqu
pvan
tcmr
injuryspecif
gene
transcript
respect
tcmrspecif
gene
overwhelmingli
involv
immun
respons
costimul
tcr
signal
pvanspecif
gene
mainli
relat
dna
replic
process
rna
polymeras
assembl
pathogen
recognit
receptor
princip
compon
analysi
use
gene
confirm
optim
separ
differ
clinic
phenotyp
valid
pvanspecif
gene
cfd
ltf
nosip
qpcr
confirm
immunohistochemistri
pvanspecif
protein
antivir
function
ltf
done
conclusionsin
conclus
even
though
pvan
tcmr
kidney
allograft
share
great
similar
gene
perturb
pvanspecif
gene
identifi
wellknown
antivir
properti
provid
tool
discern
pvan
ar
well
attract
target
ration
drug
design
sigdel
et
al
polyomavirusassoci
nephropathi
pvan
remain
import
opportunist
infect
renal
transplant
asymptomat
viremia
may
observ
transplant
recipi
may
develop
pvan
allograft
loss
occur
approxim
case
even
though
immunosuppress
condit
main
caus
viral
reactiv
latent
infect
kidney
transplant
patient
lead
develop
pvan
suggest
increas
burden
immunosuppress
appear
crucial
viral
reactiv
individu
immunesuscept
viral
infect
type
intragraft
inflamm
like
involv
pathogenesi
pvan
bkv
replic
rapidli
monitor
nucleic
acid
test
qpcr
analysi
urin
plasma
sampl
diagnosi
pvan
requir
histolog
assess
show
typic
viral
cytopath
chang
tubular
epitheli
cell
posit
immunostain
lt
antigen
simian
polyomaviru
importantli
accompani
lesion
import
tubulointerstiti
inflammatori
cell
infiltr
indistinguish
typic
histolog
pattern
observ
acut
cell
mediat
reject
tcmr
clinic
relev
sinc
therapeut
approach
oppos
pvan
treatment
fundament
focus
progress
reduct
immunosuppress
eventu
adjuv
medic
wherea
tcmr
requir
addit
rescu
immunosuppress
therapi
therefor
accur
recognit
pvanassoci
molecular
fingerprint
could
help
better
discrimin
process
provid
new
insight
pathogen
mechan
diseas
gene
express
studi
biopsi
sampl
pvan
tcmr
focus
specif
gene
pcr
analysi
report
similar
overexpress
transcript
associ
similar
cell
activ
costimul
pathway
perforin
respect
likewis
urin
increas
inflammatori
cytokin
similar
tcmr
also
shown
pvan
patient
howev
evalu
use
highthroughput
microarray
analysi
pvantcmr
tissu
allograft
sampl
significantli
enrich
genom
pictur
patholog
featur
scarc
recent
lubetzki
et
al
investig
genom
pvan
mainli
whole
blood
reduc
number
tissu
allograft
sampl
microarray
analysi
author
report
significantli
increas
pathogenesisbas
transcript
activ
cytotox
cell
natur
killer
cell
pvan
resembl
tcmr
suggest
involv
adapt
innat
immun
set
aim
obtain
deeper
understand
main
molecular
mechan
take
place
inflammatori
process
pvan
tcmr
employ
high
throughput
microarray
analysi
kidney
allograft
biopsi
report
patholog
featur
overlap
relev
number
inflammatori
cytotox
pathogenesisrel
transcript
pvan
also
show
differenti
upregul
genetranscript
relat
immun
respons
organ
particularli
viral
infect
importantli
significantli
overexpress
gene
gene
product
protein
pvan
patient
confirm
qpcr
ihc
studi
compris
posttranspl
renal
allograft
biopsi
normal
function
graft
without
subclin
reject
injuri
sta
interstiti
fibrosistubular
atrophi
ifta
uniqu
pediatr
adolesc
kidney
allograft
recipi
year
age
tabl
patient
receiv
immunosuppress
regimen
consist
combin
tacrolimu
prograf
astella
pharma
mycophenol
mofetil
cellcept
hoffmanla
roch
daclizumab
zenapax
hoffmanla
roch
thymoglobulin
sanofi
induct
patient
receiv
steroidavoid
regimen
other
receiv
steroidbas
immunosuppress
regimen
previous
describ
clinic
histolog
demograph
characterist
collect
biopsi
subset
biopsi
pvan
tcmr
sta
phenotyp
match
major
clinic
variabl
recipi
donor
age
live
donor
kidney
time
posttranspl
immunosuppress
usag
use
select
casecontrol
stringent
analysi
pvan
biolog
tabl
diagnosi
tcmr
ifta
made
biopsi
histolog
banff
classif
ifta
sampl
show
banff
score
grade
ii
higher
without
show
specif
accompani
lesion
ar
pvan
defin
posit
polyomaviru
pcr
peripher
blood
togeth
posit
stain
concomit
renal
allograft
biopsi
accord
banff
criteria
small
number
patient
bk
dna
replic
evid
pvan
biopsi
patient
categor
bkvb
bk
viremia
blood
includ
global
gene
express
first
phase
analysi
tabl
figur
ethic
committe
stanford
univers
medic
school
ucsf
medic
center
approv
studi
patientsguardian
provid
inform
consent
particip
research
full
adher
declar
helsinki
clinic
research
activ
report
consist
principl
declar
istanbul
outlin
declar
istanbul
organ
traffick
transplant
tourism
needl
biopsi
collect
time
biopsi
procedur
immedi
submerg
rnalat
qiagen
valencia
ca
store
use
gene
express
analysi
purpos
total
rna
extract
hybrid
affymetrix
genechip
human
genom
plu
array
previous
describ
naesen
et
al
nine
repres
case
kidney
allograft
biopsi
pvan
tcmr
sta
stain
overexpress
transcript
pvan
kidney
biopsi
determin
extent
renal
damag
classifi
differ
phenotyp
pvan
tcmr
sta
renal
biopsi
analyz
blind
pathologist
biopsi
probe
rabbit
polyclon
lactoferrin
abcam
cambridg
rabbit
polyclon
ifninduc
transmembran
abcam
cambridg
becton
dickinson
madrid
spain
immun
stain
formalinfix
paraffinembed
tissu
perform
describ
previous
posit
control
ltf
human
tonsil
liver
carcinoma
kidney
allograft
paraffinembed
tissu
use
posit
control
respect
quantifi
ltf
express
semi
quantit
score
differ
compart
kidney
glomeruli
vessel
tubuli
interstitium
use
differenti
express
gene
biopsi
group
identifi
use
empir
bay
moder
ttest
use
benjaminihochberg
adjust
adjust
program
altanalyz
version
comparison
fdr
adjust
p
use
filter
identifi
differenti
express
gene
probe
set
analyz
use
goelit
version
avail
default
annot
resourc
identifi
enrich
biolog
pathway
ontolog
geneset
evalu
immun
cell
infiltr
immun
celltyp
specif
marker
comput
infer
use
new
marker
identif
algorithm
lineageprofil
appli
larg
publish
microarray
studi
use
goelit
princip
compon
analysi
pca
express
cluster
hierarch
hopach
pathway
filter
visual
also
perform
altanalyz
use
default
paramet
raw
data
set
biopsi
includ
deposit
gene
express
omnibu
timefram
period
studi
uniqu
pediatr
kidney
allograft
biopsi
indic
either
caus
protocol
initi
includ
subsequ
sampleset
match
demograph
includ
gene
express
analysi
patient
found
polyomavirusassoci
nephropathi
pvan
stage
c
stage
b
pure
cell
mediat
reject
tcmr
consid
patient
stabl
function
graft
sta
abnorm
observ
biopsi
shown
tabl
differ
regard
main
clinic
demograph
characterist
donor
recipi
age
gender
type
mainten
induct
immunosuppress
number
previou
transplant
type
transplant
biopsi
perform
first
month
transplant
either
protocol
month
caus
allograft
dysfunct
presenc
bk
dna
replic
peripher
blood
time
assess
allograft
function
differ
group
acut
inflammatori
banff
score
tubuli
interstitium
renal
allograft
compart
significantli
higher
among
pvan
tcmr
compar
sta
patient
mean
serum
creatinin
valu
select
tcmr
patient
significantli
higher
mgdl
mean
serum
creatinin
valu
select
sta
patient
mgdl
p
rel
lower
serum
creatinin
seen
ar
cohort
function
pediatr
cohort
per
definit
pvan
patient
show
posit
immunostain
bk
dna
replic
peripher
blood
five
patient
bk
viru
presenc
blood
bkvb
includ
cohort
normal
biopsi
first
unsupervis
hierarch
cluster
analysi
perform
among
posttranspl
renal
allograft
biopsi
aim
broad
gene
express
pictur
use
top
rank
probeset
base
fdr
adjust
ftest
pvalu
p
increas
express
analysi
indic
global
gene
express
pattern
sampl
classifi
pvan
larg
similar
tcmr
sampl
compar
normal
kidney
biopsi
figur
biopsi
bkvb
align
normal
biopsi
studi
separ
phenotyp
top
gene
enrich
immun
system
process
immun
respons
next
order
compar
studi
popul
select
pvan
tcmr
patient
best
demograph
match
sta
patient
analysi
fdr
adjust
pvalu
criteria
p
total
probeset
show
tcmr
specif
regul
probeset
significantli
upregul
significantli
downregul
fdr
adjust
pvalu
criteria
p
total
probset
show
pvan
specif
regul
probeset
significantli
upregul
significantli
downregul
among
upregul
gene
probeset
common
tcmr
pvan
among
downregul
gene
probeset
common
tcmr
pvan
tissu
use
principl
compon
analysi
pca
take
account
top
rank
probeset
base
fdr
adjust
pvalu
p
increas
express
signific
cluster
gene
observ
among
tcmr
sta
well
pvan
sta
pvan
tcmr
sampl
cluster
togeth
sampl
type
use
pca
plot
supplement
figur
aim
identifi
critic
pvan
injuryspecif
gene
tcmr
increas
stringenc
specif
p
valu
fold
increas
express
result
uniqu
gene
increas
pvan
supplement
tabl
uniqu
gene
increas
tcmr
compar
sta
kidney
biopsi
tcmrspecif
probeset
signific
pvan
sta
individu
basic
involv
cell
receptor
itk
signal
cytotox
lymphocyt
well
relat
cellular
movement
lymphocyt
regard
uniqu
probeset
significantli
enrich
pvan
tcmr
sta
patient
mainli
involv
dna
replic
rna
bind
ltf
nosip
assembl
rna
polymeras
pathogen
recognit
receptor
cfd
indic
princip
compon
analysi
hopach
gene
cluster
pvan
specif
gene
optim
separ
sta
tcmr
pvan
sampl
achiev
rel
prior
gene
set
figur
determin
function
relev
gene
enrich
pvan
tcmr
perform
comprehens
pathwaygeneset
analysi
use
softwar
goelit
analysi
show
enrich
distinct
set
pathway
immun
system
relat
pathway
complement
cascad
tcr
signal
innat
immun
system
adapt
immun
system
specif
tcmr
associ
gene
wherea
pvan
associ
gene
enrich
dna
replic
pathway
mrna
process
ribosom
scan
viral
mrna
translat
etc
metabol
pathway
urea
cycl
gluconeogenesi
tca
cycl
etc
demonstr
distinct
molecular
event
occur
time
tcmr
pvan
figur
order
valid
pvan
specif
gene
express
data
gene
ltf
cfd
nosip
select
qpcr
valid
illustr
figur
overexpress
gene
pvan
vs
sta
also
pvan
vs
tcmr
confirm
independ
set
pvan
ar
sta
fold
increas
gene
express
lactotransferrin
ltf
pvan
signific
compar
ar
sta
ii
complement
factor
cfd
pvan
signific
compar
ar
sta
iii
ribosom
protein
pvan
signific
compar
ar
sta
iv
nitric
oxid
synthas
interact
protein
nosip
pvan
signific
compar
ar
sta
use
immunohistochemistri
ihc
analysi
assess
express
gene
transcript
ltf
protein
level
transcript
highli
upregul
kidney
biopsi
pvan
compar
tcmr
sta
previous
report
antivir
properti
ltf
figur
shown
figur
ltf
express
significantli
higher
tubuloepitheli
cell
within
mononuclear
cellular
infiltr
pvan
patient
compar
sta
tcmr
kidney
transplant
recipi
advent
pvan
still
major
concern
kidney
transplant
account
main
caus
allograft
loss
explain
great
part
rather
poor
understand
domin
mechan
diseas
wide
accept
fact
recogn
pvan
earli
possibl
key
factor
increas
likelihood
success
still
remain
unclear
best
treatment
approach
follow
studi
use
highthroughput
microarray
analysi
demonstr
inflammatori
process
occur
pvan
tcmr
either
due
protect
antivir
allogen
immun
respons
respect
merg
remark
similar
transcript
gene
pattern
essenti
associ
effector
immun
pathway
adapt
innat
immun
report
earlier
research
pvan
tcmr
share
import
similar
gene
express
level
help
explain
difficulti
differenti
type
diseas
regard
mannon
et
al
evalu
target
gene
qpcr
kidney
allograft
biopsi
recipi
pvan
tcmr
patient
stabl
allograft
function
show
despit
significantli
high
resembl
gene
express
pvan
tcmr
transcript
certain
molecul
associ
graft
fibrosi
marker
epithelialmesenchym
transform
emt
significantli
higher
pvan
specimen
suggest
higher
profibrogen
transcript
profil
pvan
tcmr
patient
higher
tissu
chronic
pvan
patient
sampl
may
also
explain
observ
differ
tcmr
pvan
relat
glucos
protein
metabol
gene
furthermor
recent
studi
lubetzki
cowork
evalu
gene
express
whole
blood
well
kidney
tissu
allograft
sampl
pvan
tcmr
kidney
transplant
recipi
studi
shown
high
level
proinflammatori
molecul
set
interferon
gammainduc
chemokin
well
cytokin
particularli
high
patient
high
bk
dna
replic
studi
valid
pvanspecif
gene
qpcr
confirm
use
ihc
illustr
potenti
function
relev
particular
transcript
uniqu
express
pvan
biopsi
compar
reject
patient
firstli
lactotransferrin
ltf
member
transferrin
famili
found
mucou
epitheli
cell
secondari
granul
polymorphonuclear
neutrophil
highli
differenti
express
among
pvan
patient
express
pvan
biopsi
significantli
higher
within
cellular
infiltr
tubuloepitheli
cell
compar
biopsi
tcmr
sta
fact
ltf
shown
play
key
role
defens
variou
pathogen
microorgan
inhibit
differ
envelop
nake
viru
differ
viruscel
system
addit
experiment
anim
model
shown
oral
administr
ltf
peptid
thereof
effect
reduc
bacteri
infect
inflamm
urinari
tract
possibl
transfer
ltf
peptid
site
infect
via
renal
secret
note
ltf
treatment
evalu
shown
prevent
earli
step
bk
viru
infect
vitro
like
interact
bk
viral
capsid
structur
find
relev
sinc
high
express
ltf
transcript
kidney
allograft
infect
bk
might
express
physiolog
protect
respons
host
viru
order
overcom
viral
infect
observ
increas
express
gene
associ
tca
cycl
urea
cycl
gluconeogenesi
biolog
plausibl
even
though
report
increas
metabol
bkv
infect
alter
metabol
especi
glucos
metabol
tca
cycl
observ
case
cytomegaloviru
infect
intuit
assum
success
replic
viru
infect
cell
requir
environ
suitabl
increas
suppli
nutrient
energi
macromolecular
synthesi
reflect
upregul
gene
express
gene
relat
metabol
pathway
complment
factor
cfd
also
upregul
pvan
serin
proteas
cleav
factor
b
result
gener
bb
format
altern
pathway
convertas
key
system
immun
surveil
homeostasi
increas
express
cfd
complement
gene
show
activ
complement
system
time
viral
infect
increas
gener
nitric
oxid
due
viral
infect
harm
nosip
gene
upregul
pvan
neg
regul
nitric
oxid
product
induc
transloc
actin
cytoskeleton
inhibit
enzymat
activ
furthermor
anoth
highli
upregul
gene
observ
within
pavn
patient
compar
tcmr
stabl
individu
ifninduc
transmembran
transcript
interestingli
ifitm
protein
famili
ubiquit
express
restrict
factor
mediat
potent
ifninduc
antivir
activ
inhibit
viral
entri
particularli
step
membran
fusion
nevertheless
antivir
activ
well
character
rna
virus
shown
induc
opposit
effect
enhanc
infect
sever
dna
virus
inde
demonstr
antivir
activ
ifitm
protein
like
mediat
prevent
endosom
fusion
viral
entri
cytosol
well
inhibit
viral
entri
prevent
escap
endocyt
pathway
particularli
among
dna
viru
therefor
overproduct
molecul
pvan
patient
could
hypothes
repres
signal
persist
dna
replic
illustr
aggress
natur
bkv
infect
kidney
transplant
inde
coloc
close
proxim
ltf
tubular
cell
show
bk
viral
inclus
corrobor
previous
report
data
figur
summari
even
though
pvan
tcmr
kidney
allograft
share
great
similar
gene
perturb
particular
pvanspecif
transcript
differenti
express
encod
molecul
wellknown
antivir
properti
track
effector
molecul
context
bk
viru
infect
may
lead
discoveri
novel
potenti
therapeut
target
may
eventu
overcom
develop
persist
bkv
infect
kidney
transplant
refer
web
version
pubm
central
supplementari
materi
comprehens
pathwaygeneset
analysi
use
softwar
goelit
perform
identifi
molecular
pathway
enrich
pvan
compar
tcmr
result
enrich
distinct
set
pathway
immun
system
relat
pathway
complement
cascad
tcr
signal
innat
immun
system
adapt
immun
system
specif
tcmr
wherea
pvan
associ
gene
enrich
dna
replic
pathway
mrna
process
ribosom
scan
viral
mrna
translat
etc
metabol
pathway
urea
cycl
gluconeogenesi
tca
cycl
etc
specif
pvan
demonstr
distinct
molecular
event
occur
time
tcmr
pvan
qpcr
valid
pvan
specif
gene
order
valid
pvan
specif
gene
express
data
gene
ltf
cfd
nosip
select
qpcr
valid
overexpress
gene
pvan
vs
sta
also
pvan
vs
tcmr
confirm
gene
express
lactotransferrin
ltf
pvan
signific
compar
ar
sta
b
complement
factor
cfd
pvan
signific
compar
ar
sta
c
ribosom
protein
pvan
signific
compar
ar
sta
nitric
oxid
synthas
interact
protein
nosip
pvan
signific
compar
ar
sta
first
third
quartil
end
box
median
indic
horizont
line
interior
box
maximum
minimum
end
whisker
